Free Trial

Zymeworks (ZYME) Insider Trading & Ownership

Zymeworks logo
$13.28
-0.42 (-3.07%)
(As of 04:17 PM ET)

Zymeworks (NYSE:ZYME) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
1.22%
Number Of
Insiders Buying
(Last 12 Months)
0
Number Of
Insiders Selling
(Last 12 Months)
3
Amount Of
Insider Selling
(Last 12 Months)
$436,263.55
Get ZYME Insider Trade Alerts

Want to know when executives and insiders are buying or selling Zymeworks stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

ZYME Insider Buying and Selling by Quarter

Zymeworks Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/8/2024Christopher AstleCFOSell1,431$11.22$16,055.82  
1/8/2024Kenneth GalbraithCEOSell5,706$11.22$64,021.32  
1/8/2024Paul Andrew MooreInsiderSell2,339$11.22$26,243.58  
1/5/2024Christopher AstleCFOSell4,563$10.65$48,595.95  
1/5/2024Kenneth GalbraithCEOSell18,198$10.65$193,808.70  
1/5/2024Paul Andrew MooreInsiderSell7,460$10.65$79,449.00  
12/11/2023Christopher AstleCFOSell886$9.13$8,089.18  
(Data available from 1/1/2013 forward)

ZYME Insider Trading Activity - Frequently Asked Questions

The list of insiders at Zymeworks includes Christopher Astle, Ecor1 Capital, Llc, Kenneth Galbraith, Neil A Klompas, Neil Josephson, and Paul Andrew Moore. Learn more on insiders at ZYME.

1.22% of Zymeworks stock is owned by insiders. Learn more on ZYME's insider holdings.

The following insider purchased ZYME shares in the last 24 months: Ecor1 Capital, Llc ($44,875,510.00).

Insiders have purchased a total of 5,396,200 ZYME shares in the last 24 months for a total of $44,875,510.00 bought.

The following insiders have sold ZYME shares in the last 24 months: Christopher Astle ($78,071.82), Kenneth Galbraith ($257,830.02), Neil A Klompas ($23,309.91), Neil Josephson ($20,047.50), and Paul Andrew Moore ($105,692.58).

Insiders have sold a total of 46,922 Zymeworks shares in the last 24 months for a total of $484,951.83 sold.

Zymeworks Key Executives

  • Mr. Kenneth H. Galbraith C.A. (Age 61)
    Chairman of the Board & CEO
    Compensation: $1.04M
  • Dr. Paul Moore Ph.D. (Age 56)
    Chief Scientific Officer
    Compensation: $872.67k
  • Ms. Leone D. Patterson M.B.A. (Age 62)
    CFO, EVP & Chief Business Officer
  • Mr. Mark Hollywood (Age 54)
    Executive VP and Head of Technical & Manufacturing Operations
  • Mr. Daniel Dex J.D.
    Ph.D., Senior VP, Corporate Secretary & General Counsel
  • Diana Papove
    Senior Manager of Corporate Communications
  • Dr. Lindsey Foulkes B.Sc.
    Ph.D., Vice President of Corporate Development
  • Ms. Laura O'Connor
    Vice President of Human Resources & DEI
  • Dr. Jeffrey Smith M.D.
    Executive VP & Chief Medical Officer
  • Dr. Josemund Menezes MBBS
    Managing Director of Early-Stage Development for Asia Pacific


This page (NYSE:ZYME) was last updated on 11/1/2024 by MarketBeat.com Staff
From Our Partners